NorthWest Biotherapeutics Inc (NWBO)

[ae kusterer]

exwannabe: When you say " Even an exact copy of DCVax-L would not infringe as those patents are all expired." , you are barking up the wrong tree. UCLA, the MHRA, Oncovir, Nature , and Roswell would not be doing transactions with $nwbo unless their patent attorneys had assured those institutions that dc vax l and dc vax direct are proprietray therapies with long term patent protection.I suggest you study the last five years of twitter postings by @henrymuney . He is the best $nwbo patent researcher. Also, @hoffmann6383 has analyzed several NWBO patent situations.

P.S. Your nwbo disinformation is beyond the pale. It strikes me a criminal, warranting free room and board so you have time to think over whether or not you want to remail a U.S. citizen.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174785640

exwannabe

Re: Horseb4CarT post# 707358

Sunday, July 21, 2024 11:25:17 AM

Post#
707395
of 707591
Does this encroach on DCVax patents?


It certainly does not now, as clinical trials are fair use even if infringing.

It does not seem particularly likely it would infringe. It s clearly a fairly different process. Remember that ATL-DCs existed even before NWBO did. There are many DCs out there that do infringe. Even an exact copy of DCVax-L would not infringe as those patents are all expired.

Sunday, July 21, 2024 11:25:17 AM

" Even an exact copy of DCVax-L would not infringe as those patents are all expired."

#DCVax-L facts. Match the references to the items in the screenshot.

1. SAP https://t.co/1bPnvQoKBT

2. Contemporaneous External Controls https://t.co/G6BhQPSeZM

3. DCVax-L = ATL-DC https://t.co/QbqNHXYKYK

4. Crossover arm https://t.co/KX6dqxmFOU

5. Patient-level data$NWBO pic.twitter.com/3ID2wMKBT7

— Henry (@HenryMuney) January 4, 2023

https://nature.com/articles/s41467-024-48073-y

https://nwbio.com/northwest-biotherapeutics-announces-exclusive-in-license-of-portfolio-of-dendritic-cell-technology-and-intellectual-property/

https://nwbio.com/northwest-biotherapeutics-and-advent-bioservices-announce-receipt-of-license-for-commercial-manufacturing-at-sawston-u-k-facility/

"Competing interests
Andres Salazar is the Founder, CEO and Scientific Director for Oncovir, which provided the TLR agonist (Poly-ICLC) used in the trial. Linda M. Liau is a member of the Scientific Advisory Board for Northwest Bioetherapeutics, Inc, which has licensed the DC vaccine technology. All others declare no competing interests."
Quote
Henry
@HenryMuney
·
Jan 4, 2023
#DCVax-L facts. Match the references to the items in the screenshot.

1. SAP https://cdn.jamanetwork.com/ama/content_public/journal/oncology/0/coi220066supp1_prod_1668698380.81699.pdf

2. Contemporaneous External Controls https://x.com/henrymuney/sta/HenryMuney/status/1597107887922298882

3. DCVax-L = ATL-DC https://x.com/henrymuney/sta/HenryMuney/status/1532814676001640448

4. Crossover arm https://x.com/henrymuney/sta/HenryMuney/status/1593291205449637890

5. Patient-level data

$NWBO https://pic.x.com/3id2wmkbt7
Show more
Show this thread